Cardiac mRNA complications as of Sept 2021 - mounting evidence as data comes in

[AnnieA]

June 2021--US Vaccine Advisory numbes (CDC cites this):

4.1 per million doses

August 2021-- JAMA (Journal of the American Medical Association) numbers

Myocarditis (1.0 per 100 000) ... pericarditis 1.8 per 100 000).

Sept 2021--University of Ottawa Heart Institute pre-print

Combined myocarditis/pericarditis 10 per 10,000

Studies in JAMA and from the University of Ottawa note that incidences of cardiac adverse reactions are likely higher due to missed cases upon admission due to lack of current awareness that the heart conditions are related to the mRNA vaccines.

This is a good reason for those previously infected or vaccinated to base initial vaccines and boosters on individual antibody levels.

 

[AnnieA]

Information such is this is why my physician and I agree I should wait for the vaccine. Inflammatory adverse reactions including those that induce autoimmunity have been the reason mRNA delivered therapeutics have never successfully made it through clinical trials.

Early on in the rollout, I found this February 2019, pre-Covid overview of mRNA vaccine technology authored by GlaxoSmithKline researchers.

From the 2019 article Conclusion and Perspectives section:

Several questions remain unanswered, including the relative utility of nucleoside-modified versus unmodified mRNAs, self-amplifying mRNAs versus conventional mRNAs, the most efficient and safest delivery system, and the best route of administration. In addition, the safety and tolerability profile of these emerging technologies needs to be fully elucidated, including the relative roles of the RNA and delivery systems in stimulating proinflammatory innate immune responses, and how the doses of these components contribute. A further understanding of the sequence of events leading to antigen expression, innate activation, and adaptive responses could guide the development of a portfolio of mRNA molecules and delivery systems with differential attributes. This will create a toolbox to tackle different applications, such as prophylactic versus therapeutic vaccines, infectious disease versus host disease (e.g., cancer) targets, or delivery of vaccine antigen versus therapeutic molecules (e.g., molecular antibodies).​

​

The next 5 years will be very important for the field of mRNA vaccines, with results from several human clinical trials providing a clearer understanding of the true prospects of the technology and insights into the strengths and weaknesses of the various mRNA technologies and delivery systems under development.​

​

Edit to say: I think the Covid vaccines have very much mitigated severity and mortality and have been invaluable in lessening the impact of the pandemic. I also think that they can be improved upon, but don't know if pharmaceutical companies will go to the expense to do so unless data increasingly shows evidence of harm to the point that global governmental entities force reformulations.